(The JAMA Network Journals) Among women with metastatic breast cancer, treatment with a drug that is biosimilar to the breast cancer drug trastuzumab resulted in an equivalent overall response rate at 24 weeks compared with trastuzumab, according to a study published online by JAMA.
from EurekAlert! - Social and Behavioral Science http://ift.tt/2gMEcG8
No comments:
Post a Comment